

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Mabwell (Shanghai) Bioscience Co., Ltd.

邁威(上海)生物科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2493)

CHANGE OF AUTHORISED REPRESENTATIVE

The board (the **"Board"**) of directors (the **"Directors"**) of Mabwell (Shanghai) Bioscience Co., Ltd. (the **"Company"**) announces that with effect from June 18, 2026:

- (i) Mr. HU Huiguo ceased to act as the authorised representative of the Company under the Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the **"Authorised Representative"**); and
- (ii) Mr. HUA Jun, an executive Director of the Company, has been appointed to act as the Authorised Representative.

Following the appointment of Mr. HUA Jun, the Authorised Representatives of the Company are Mr. HUA Jun and Ms. LEUNG Kwan Wai.

By Order of the Board
Mabwell (Shanghai) Bioscience Co., Ltd.
Dr. Liu Datao
Chairman of the Board and Executive Director

Shanghai, the PRC, June 18, 2026

As at the date of this announcement, the directors of the Company are: (i) Mr. Tang Chunshan, Dr. Liu Datao (Chairman of the Board), Dr. Wu Hai, Mr. Hua Jun and Dr. Gui Xun as executive directors and (ii) Mr. Qin Zhengyu, Mr. Zhou Rui, Ms. Li Fan and Ms. Wang Fang as independent non-executive directors.